Quote:

---

Dual Targeting: By combining a CCR5 blocker with a VEGF inhibitor, the conjugate can simultaneously target two critical pathways involved in tumor growth and metastasis. CCR5 is involved in tumor cell migration and metastasis, while VEGF promotes angiogenesis (the formation of new blood vessels) that supply the tumor with nutrients12.

---

AI does not know that CCR5 blockade downregulates VEGF which is why leronlimab has been shown to inhibit angiogenesis making another VEGF inhibitor unnecessary.

Quote:

---

Minimized Off-Target Effects: Targeted delivery reduces the exposure of healthy tissues to the VEGF inhibitor, potentially minimizing side effects such as hypertension and impaired wound healing, which are common with systemic VEGF inhibition3.

---

CCR5 blockade lowers hypertension and of course leronlimab is self targeting to CCR5.

Quote:

---

Plus, such a conjugate would be patentable, would it not?

---

It would be patentable, but conjugating leronlimab with a drug that has a part of the same effect as leronlimab would be pointless. It would also require a larger dose because the binding to VEGF would mean not binding to CCR5. It would also carry over the side effects of the VEGF inhibitor. Roche could try it. But when it's shown that it's no better than leronlimab alone with more side effects it's wasted money.